Atea Pharmaceuticals, Inc.
-
Ticker
AVIR
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in Boston, Massachusetts
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea is developing novel product candidates to treat single
…More stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates through using its internal discovery capabilities augmented by in-licensing. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV).
REPORT RATINGS
5.0 / 5.0 (1)
Atea Pharmaceuticals, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Atea Pharmaceuticals, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports